WO2012021841A3 - Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof - Google Patents

Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof Download PDF

Info

Publication number
WO2012021841A3
WO2012021841A3 PCT/US2011/047650 US2011047650W WO2012021841A3 WO 2012021841 A3 WO2012021841 A3 WO 2012021841A3 US 2011047650 W US2011047650 W US 2011047650W WO 2012021841 A3 WO2012021841 A3 WO 2012021841A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncogenic
antibody molecules
isoform
growth factor
disclosed
Prior art date
Application number
PCT/US2011/047650
Other languages
French (fr)
Other versions
WO2012021841A2 (en
Inventor
Xiao-Jia Chang
Ullrich S. Schwertschlag
Katherine Jane Turner
Original Assignee
Attogen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attogen Inc. filed Critical Attogen Inc.
Priority to CN201180038950.8A priority Critical patent/CN103201287B/en
Priority to EP11817134.7A priority patent/EP2603521A4/en
Publication of WO2012021841A2 publication Critical patent/WO2012021841A2/en
Publication of WO2012021841A3 publication Critical patent/WO2012021841A3/en
Priority to US13/765,236 priority patent/US9260525B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Antibody molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding antibody molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and/or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and/or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed.
PCT/US2011/047650 2008-02-04 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof WO2012021841A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201180038950.8A CN103201287B (en) 2010-08-12 2011-08-12 Antibody molecule of the carcinogenic isomer of fibroblast growth factor acceptor 2 and uses thereof
EP11817134.7A EP2603521A4 (en) 2010-08-12 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US13/765,236 US9260525B2 (en) 2008-02-04 2013-02-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307210P 2010-08-12 2010-08-12
US61/373,072 2010-08-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2009/033031 Continuation-In-Part WO2009100105A2 (en) 2008-02-04 2009-02-04 Inhibitors of oncogenic isoforms and uses thereof
US86601310A Continuation-In-Part 2008-02-04 2010-11-22
US13/765,236 Continuation-In-Part US9260525B2 (en) 2008-02-04 2013-02-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Publications (2)

Publication Number Publication Date
WO2012021841A2 WO2012021841A2 (en) 2012-02-16
WO2012021841A3 true WO2012021841A3 (en) 2012-06-14

Family

ID=45568223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/047650 WO2012021841A2 (en) 2008-02-04 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Country Status (3)

Country Link
EP (1) EP2603521A4 (en)
CN (1) CN103201287B (en)
WO (1) WO2012021841A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
AU2009231570A1 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
AU2011253101A1 (en) 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US9714298B2 (en) * 2012-04-09 2017-07-25 Daiichi Sankyo Company, Limited Anti-FGFR2 antibodies and methods of use thereof for treating cancer
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
KR102516152B1 (en) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. Afucosylated anti-fgfr2iiib antibodies
WO2016171107A1 (en) * 2015-04-20 2016-10-27 第一三共株式会社 Detection of fgfr2
BR112018010410A8 (en) * 2015-11-23 2019-02-26 Five Prime Therapeutics Inc method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells
CN107513106A (en) * 2016-06-17 2017-12-26 艾托金生物医药（苏州）有限公司 Anti- FGFR2-IIIc monoclonal antibodies, hybridoma cell strain and application
EP3519826A1 (en) * 2016-09-27 2019-08-07 The University of The Highlands and Islands Antigen biomarkers
EP3624837A1 (en) 2017-05-16 2020-03-25 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
KR102539445B1 (en) * 2020-11-25 2023-06-05 (주)케어젠 Peptide Having Activity of Protecting Cell Damage From Particulate Matter and Uses Thereof
CN113150135B (en) * 2021-04-14 2022-09-20 中山大学 Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019845A1 (en) * 2003-07-22 2005-01-27 Schering Aktiengesellschaft RG1 antibodies and uses thereof
US20080260748A1 (en) * 2005-05-12 2008-10-23 Oncotherapy Science, Inc. Methods for Damaging Cells Using Effector Function of Anti-Dsc2 Antibody
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
US20090137002A1 (en) * 2007-07-31 2009-05-28 Heike Petrul Anti ephb4 antibodies and antibody fragments
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
US20100196364A1 (en) * 2008-11-07 2010-08-05 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019845A1 (en) * 2003-07-22 2005-01-27 Schering Aktiengesellschaft RG1 antibodies and uses thereof
US20080260748A1 (en) * 2005-05-12 2008-10-23 Oncotherapy Science, Inc. Methods for Damaging Cells Using Effector Function of Anti-Dsc2 Antibody
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
US20090137002A1 (en) * 2007-07-31 2009-05-28 Heike Petrul Anti ephb4 antibodies and antibody fragments
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
US20100196364A1 (en) * 2008-11-07 2010-08-05 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2603521A4 *

Also Published As

Publication number Publication date
CN103201287A (en) 2013-07-10
WO2012021841A2 (en) 2012-02-16
CN103201287B (en) 2016-04-13
EP2603521A2 (en) 2013-06-19
EP2603521A4 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
WO2012021841A3 (en) Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A3 (en) Inhibitors of oncogenic isoforms and uses thereof
WO2009120899A3 (en) G coupled protein receptors associated with myelogenous haematological proliferative disorders and uses thereof
WO2011143562A3 (en) Il-1 binding proteins
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2012067970A3 (en) Transcriptional repression leading to parkinson's disease
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
PL2342233T3 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2012061835A3 (en) Apparatus and method for non-invasively detecting diseases that affect structural properties in biological tissues
MX359551B (en) Targeted binding agents against b7-h1.
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
GB0921349D0 (en) Ex vivo methods for validating substance testing with human organs and or tissues
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
EP2209495A4 (en) Taz/wwtr1 for diagnosis and treatment of cancer
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2011086174A3 (en) Diagnostic gene expression platform
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
EP2446048A4 (en) Methods and kits for measuring enzyme activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817134

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011817134

Country of ref document: EP